The city of Raleigh, North Carolina, currently has 3 active clinical trials seeking participants for Crohn's Disease research studies.
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab together with ustekinumab in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: Wake Research Associates, LLC, Raleigh, North Carolina
Conditions: Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/07/2024
Locations: Duke Health's Brier Creek Medical Pavilion (recruitment and study activities), Raleigh, North Carolina
Conditions: Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/04/2024
Locations: Clinical Study Site, Raleigh, North Carolina
Conditions: Inflammatory Bowel Diseases, Crohn's Disease